A Longterm Prospective Real-life Experience with Leflunomide in Juvenile Idiopathic Arthritis

To describe a clinical practice with leflunomide (LEF) in juvenile idiopathic arthritis (JIA). Patients with JIA seen between May 2008 and May 2012 and considered nonresponsive to methotrexate (MTX) were given LEF and prospectively followed. Primary outcome was a 28-joint Disease Activity Score (DAS...

Full description

Saved in:
Bibliographic Details
Published in:Journal of rheumatology 2014-02, Vol.41 (2), p.338-344
Main Authors: DE CASTRO ALCANTARA, Antonia Célia, CHAVES LEITE, Christiane Araújo, MELO LEITE, Ana Caroline Rocha, COSTA SIDRIM, José Julio, SARAIVA SILVA, Francisco, CASTRO ROCHA, Francisco Airton
Format: Article
Language:English
Subjects:
Adolescent
Antirheumatic Agents - therapeutic use
Arthritis, Juvenile - drug therapy
Biological and medical sciences
Bones, joints and connective tissue. Antiinflammatory agents
Child
Child, Preschool
Diseases of the osteoarticular system
Drug Therapy, Combination
Female
Health Status
Humans
Inflammatory joint diseases
Isoxazoles - therapeutic use
Male
Medical sciences
Methotrexate - therapeutic use
Pharmacology. Drug treatments
Prospective Studies
Severity of Illness Index
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe a clinical practice with leflunomide (LEF) in juvenile idiopathic arthritis (JIA). Patients with JIA seen between May 2008 and May 2012 and considered nonresponsive to methotrexate (MTX) were given LEF and prospectively followed. Primary outcome was a 28-joint Disease Activity Score (DAS28) of low disease activity (< 3.2) in less than 6 months. Childhood Health Assessment Questionnaire (CHAQ) scores and safety data were recorded. Forty-three patients (33 female) were included with 25 (58.1%) polyarticular, 10 oligoarticular (7 extended; 3 persistent), 6 systemic, and 2 enthesitis-related. Ten (23.2%) were rheumatoid factor-positive and 7 (16.3%) had antinuclear antibodies. Prior drugs other than MTX: 11 (25.5%) chloroquine diphosphate + MTX and 2 (4.6%) sulfasalazine + MTX; mean prednisone dose was 6.4 ± 9.3 mg. The MTX dose prior to LEF was 14.5 ± 4.5 mg/m(2)/week. LEF dose and duration of therapy were 16.6 ± 5.2 mg/d and 3.6 ± 2.2 years, respectively. Nineteen patients (44.2%) interrupted LEF: 1 entered remission, 11 were nonresponsive, and 7 were intolerant (16.2%). Baseline DAS28 (5.57 ± 0.7) dropped to 3.7 ± 1.2 at final analysis (p < 0.001) and 16 patients (37.2%) had a low DAS28 [< 3.2; 12 (27.9%) while taking LEF + MTX and 4 (9.3%) while taking monotherapy]. At last followup, the number of patients with DAS28 > 5.1 dropped from 34 (79%) to 9 (20.9%) and CHAQ scores from 0.86 ± 0.7 to 0.44 ± 0.5 (p < 0.001). LEF isolated or combined with MTX is effective and safe to treat JIA in patients refractory to MTX.
ISSN:0315-162X
1499-2752
DOI:10.3899/jrheum.130294